Moderna, Inc.

We are mRNA. And mRNA is us.

Every day, we come together to create the blueprints needed to fight and eradicate diseases, and to help people live healthier lives. And the world has witnessed the powerful benefits of our platform technology.

With mRNA technology, we are completely reimagining how medicines are created and delivered. And in the process, we’re launching an entirely new industry, one fueled by deep care for our teams as well as for others.

Through the power of mRNA, we’re giving our people a platform to change medicine—and an opportunity to change the world.

Come with us as we pursue the uncharted reaches of possibility and make your mark on the future of medicine: modernatx.com/careers

200 Technology Square
Cambridge, MA

Tel: 617-714-6500

Visit website

Email Us

Stock Symbol: MRNA
Stock Exchange: USNASDAQ GS

Changing the future of medicine starts with our people. Across Moderna, our colleagues are working to make the impossible possible, and our goal is to support them every step of the way. With a global team and a unique culture, driven by the company’s values and mindsets, Moderna’s mission is to deliver the greatest possible impact to people through mRNA medicines.

Every Role Matters, Enabling Transformative Mission

At Moderna, our changemakers are actively building a better future, one innovation at a time. We recently asked Keke if she could create a six-word story about what being a changemaker meant to her.

Read Keke’s Story

Take your moment with benefits

We know that you will give us your all and we want to make sure that we’re doing the same for you and the people closest to you. We’re on this incredible journey of pushing past the possible together, which is why we provide paramount support for both you and your family.

Learn More

NEWS

Drug Development

At Least 4 Vaccine Candidates Backed by U.S. Government Predicted to Fail, Analytics Group Says

The U.S. government has financially backed the development of six different vaccine candidates aimed at the novel coronavirus. Although billions of dollars have been appropriated to the pandemic, at least four of those potential preventative treatments are predicted to fail in the clinic.

September 2, 2020

3 min read

Alex Keown

Drug Development

Clinical Catch-Up: August 24-28

As August wraps up, there were still clinical trial announcements, although fewer than earlier this summer. Here’s a look.

August 31, 2020

5 min read

Mark Terry

Drug Development

Phase I Data Suggests Moderna’s COVID-19 Vaccine is Effective Across Age Groups

Moderna presented more detailed data from the Phase I trial of its mRNA COVID-19 vaccine at the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices today.

August 26, 2020

3 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: August 26

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 26, 2020.

August 25, 2020

4 min read

BioSpace Editorial Staff

Policy

Moderna Signs COVID-19 Vaccine Supply Deal with U.S. for $1.525 Billion

Moderna signed a contract worth up to $1.525 billion with the U.S. government to supply 100 million doses of mRNA-1273, the company’s experimental COVID-19 vaccine.

August 12, 2020

3 min read

Mark Terry

Policy

Biopharma Update on the Novel Coronavirus: August 12

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 12, 2020.

August 11, 2020

5 min read

BioSpace Editorial Staff

Drug Development

Biopharma Update on the Novel Coronavirus: August 10

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 10, 2020.

August 10, 2020

2 min read

BioSpace Editorial Staff

Policy

Biopharma Update on the Novel Coronavirus: August 5

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for August 5, 2020.

August 4, 2020

5 min read

BioSpace Editorial Staff

Business

In Abundance of Caution, Brigham & Women’s President Resigns from Moderna’s Board

As Moderna launched its Phase III clinical trial of its COVID-19 vaccine this week, a member of the company’s board of directors, Elizabeth “Betsy” Nabel, resigned to avoid any conflict of interest.

July 31, 2020

3 min read

Mark Terry

JOBS